Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates.

Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Treatments: Fibrinolytic Agents; Reteplase

Criteria

Inclusion Criteria:

1. Ischemic discomfort (squeezing, crushing, or pressure, sub-sternal, unrelated to breathing or movement), epigastric discomfort or pre-syncopal symptoms with diaphoresis, lasting > 30 minutes.

2. ST elevation > 0.1 mV in 2 or more contiguous limb leads or > 0.2 mV in 2 or more contiguous pre-cordial leads.

3. Less than 6 hours after onset of sustained chest pain.

4. Age 18 years or older.

Exclusion Criteria:

1. Chest pain described as ripping or tearing, radiating to the back and/or down the leg, and/or systolic blood pressure > 15 mmHg difference in each arm.

2. Suspected cocaine or amphetamine use within previous 3 days.

3. Known or suspected pregnancy.

4. Cardiac arrest requiring intubation.

5. Cardiac arrest requiring greater than 20 minutes CPR.

6. Coronary intervention (PTCA/stent/CABG) within previous 4 weeks.